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 Parkinson’s Disease is a neurodegenerative disease that is caused by a lack of dopamine. 
This lack of dopamine has many effects on a person’s body who has Parkinson’s Disease 
including loss of motor control, slowed movement (bradykinesia), changes in speech, impaired 
posture and balance, and muscle rigidity. The object of this paper is to explore some of the many 
different options for treatment of symptoms of Parkinson’s Disease that are currently available. 
There is not one over-arching treatment that can alleviate the symptoms that are caused by 
Parkinson’s Disease. However, if multiple treatments are used together, a patient who is 
diagnosed with Parkinson’s Disease can live their life with not as strong symptoms and are able 
to regain their freedom that this disease has taken from them.  
One sentence summary: This paper explores a few of the many different pharmacological and 











Causes of Parkinson’s Disease  
Parkinson’s Disease is an increasingly common neurodegenerative disease that currently 
has no cure. It is very common in cases where Parkinson’s has been diagnosed to see 
depigmentation of the substantia nigra. This depigmentation is thought to be present due to the 
progressive and degenerative loss of dopaminergic neurons and receptors. In this depigmented 
substantia nigra, there also seems to be the presence of intraneuronal inclusions called Lewy 
bodies.1 These Lewy bodies are commonly found in the surviving neurons that haven’t been 
degraded yet. Lewy bodies are enriched in one of the main genes thought to be the cause of 
Parkinson’s, α-synuclein, as well as many other proteins that have been ubiquitinated and await 
destruction.2 Due to the mutations in these genes and other accompanying manifestations, about 
50% of the neurons in the substantia nigra are degraded and rendered useless. This causes a 
depletion of dopamine within the striatum, which leads to a loss of control of the motor circuits 
of the body, resulting in the clinical causes of Parkinson’s that are most common in someone 
who is afflicted. The clinical signs that are most common in someone who has Parkinson’s 
Disease is muscular rigidity, slowness of movement, postural instability, and the most famous 
Figure 1. Different genes and their suggested relationships to Parkinson’s Disease. 
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one, the resting tremor. Through research and diagnostic testing, it has been found that there are 
multiple potential causes for someone being diagnosed with Parkinson’s. Most cases are thought 
to be sporadic, but there are multiple genes that have been targeted for study that when mutated, 
give rise to common and familial forms of Parkinson’s. The main genes that are currently being 
focused on are α-synuclein (SNCA), parkin, leucine-rich repeat kinase 2 (LRRK2), PTEN-
induced putative kinase 1 (PINK1), and DJ-1.3 Figure 1 above shows the different genes that 
could have a relationship with causing Parkinson’s Disease, their suggested functions, and 
reasons they are thought to be the causes for Parkinson’s Disease. SNCA and LRRK2 both are 
autosomal dominant genes that are thought to be causes of this disease.4 They are thought to be 
affected through a gain-of-function mutation or a dominant negative effect mutation on the 
protein.5 Parkin, PINK1, and DJ-1 are all 
autosomal recessive genes that when 
mutated, can have different functions then 
normal and can cause some of the effects 
that lead to Parkinson’s Disease.6 Figure 2 to 
the left is a concept map of how these 
different genes and proteins all link together 
and how their functions all can depend on 
each other. While each case of Parkinson’s 
is different, being able to narrow to the exact cause of why someone is afflicted with this disease 
is key in being able to treat this disease. There are different treatment options available for 
people diagnosed with Parkinson’s Disease, some medicinal and some non-medicinal. Different 
Figure 2. Concept map of how different genes related to Parkinson's 
disease interact.  
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routes of treatment, pharmacological and non-pharmacological, for Parkinson’s Disease, will be 
discussed in this paper. 
Current Parkinson’s Disease Treatment Options – Non-Pharmacological  
Parkinson’s Disease is a crippling neurodegenerative disease that affects many aspects of 
day to day life. While there are treatments to help aid with the symptoms that accompany this 
disease, there is no cure for Parkinson’s at this current time. However, there are a few different 
routes of treatment that patients can explore to help slow down the degeneration of motor skills 
and can help people living with Parkinson’s Disease. Montgomery claims in his review of 
rehabilitative approaches to Parkinson’s that there are multiple avenues and therapy options for 
people dealing with Parkinson’s, such as physical therapy, occupational therapy, and speech 
therapy.7 He also says that these therapy options are hopefully being used to directly modify the 
physiological processes in the brain, so people dealing with Parkinson’s can overcome the 
symptoms that Parkinson’s causes. In one research article, one of the biggest therapy strategies 
that Montgomery talks about is helping people with Parkinson’s manage their symptoms using 
neurophysiological support. Using this kind of support can help patients conceptualize their 
difficulties and alter their expectations to be able to achieve more reasonable goals and to relearn 
how to do basic tasks, if needed.7  
Movement impairments related to Parkinson’s Disease are especially difficult for almost 
all patients that are showing symptoms. Some of these movement impairments relate to 
maintaining balance while standing, losing postural stability, difficulty doing simple tasks that 
affect daily living, and frequent falls. While some of the motor ailments of Parkinson’s can be 
treated medicinally, not all of them can be treated using drugs. There are other ways to help treat 
this disease and one of them is physical activity. Physical activity has been shown to slow down 
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the deterioration of motor functions in the body and help to prolong functional independence.8 
Even after the introduction of drugs such as Levodopa, which is primarily used to treat 
Parkinson’s Disease, many doctors believed that if paired with physical activity, can help 
maximize the benefits of the medication.9 
One of the biggest non-medicinal treatment options for people with Parkinson’s is 
physical therapy. In physical therapy for Parkinson’s patients, one of the most basic styles of 
therapy is amplitude training. According to the John Hopkins Medicine official website, during 
this kind of physical therapy, a specific form of physical therapy called LSVT training is used. 
LSVT BIG stands for Lee Silverman Voice Treatment, and BIG stands for big movements. In 
this treatment option, patients make large and overexaggerated physical movements based on 
what their physical therapist says, like swinging their arms or taking really high steps. Doing 
these overexaggerated movements is thought to help retrain the muscle to do basic movements 
and to help slow down the progression of hypokinesia.10 Another form of physical therapy that 
can help people with Parkinson’s feel more confident with living day-to-day is reciprocal pattern 
therapy. This form of therapy is thought to help reinforce just basic movements that become hard 
or impossible with Parkinson’s. Some of these reciprocal behaviors are sometimes as simple as 
swinging the arms when walking or taking basic steps in front of one another while walking. 
Doing these simple behaviors over and over is thought to relearn the basic movements and 
ingrain how to do them while dealing with the symptoms of Parkinson’s.10 One aspect of life that 
Parkinson’s Disease disrupts is normal balance. The disruption of balance in everyday life can 
have a major impact on people with Parkinson’s. Balance is a combination of visual feedback 
from a certain stimulus, the balancing system in the inner ear reacting to said stimulus, and then 
the brain interpreting these two feedback mechanisms together. Balance therapy has shown in 
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different studies to be an 
exceptional tool for people with 
Parkinson’s and in turn, helping the 
patients regain their confidence in 
living with their condition. In this 
therapy style, practice balancing 
and walking in straight lines is 
done. During these therapy 
sessions, the patient is taught how 
to compensate for changes in their 
balance.10 Studies have shown that 
patients who use this type of 
physical therapy have increased 
confidence in preforming simple 
tasks, such as walking and sitting in 
a chair, which can help the patient 
to be more secure living with this 
disease. One unique way that people with Parkinson’s Disease can help keep their balance and 
posture strong is to engage in Tai Chi! In a study published in the New England Journal of 
Medicine, Tai Chi was shown to “improve strength, balance, physical function, and to prevent 
falls in older adults”.11 In the Tai-Chi study, there were 3 groups of participants. All participants 
of the trial had Parkinson’s Disease. They were broken up into different groups; one group that 
would be participating in Tai Chi for their physical activity/therapy, one group that would be 




doing Resistance training, and the last group that would be doing Stretching. Tai Chi was found 
to help reduce balance impairments, as well as add additional benefits to improved functional 
capacity and reduced falls, when compared to the other groups.11 Figure 3 above shows data and 
statistics for the three different trial groups. For most of the data, there seems to be a significant 
difference between Tai Chi and Resistance groups for some changes from the baseline in 
maximum excursion, directional control, and stride length. However, there is a significant 
difference between Tai Chi and Stretching groups in every category in the table. The significant 
difference between the Tai Chi group data and the Resistance and Stretching group data showed 
that Tai Chi was more effective at treating and empowering different basic functions for people 
dealing with Parkinson’s. One of the biggest problems with Parkinson’s Disease is a patient 
being unable to 
control their 
motor movements 
and falling, which 
can cause 
significant 
damage. Falling is 
a significant part of dealing and living with Parkinson’s due to the affected individual’s balance 
being diminished. One of the purposes of this research study was to look at the adverse effects of 
daily living and falls that participants were involved in, depending on what group of they were 
in. Figure 4 above shows data collected from participants regarding how many total falls they 
had while participating in this study. This data shows that the group that participated in Tai Chi 
had a significantly lower number of falls than the participants in the Resistance group and the 
Figure 4. Data from Tai-Chi study regarding the amount of falls each group had during the study. 
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Stretching group. Focusing on more strenuous physical therapy options, if the patient is able to, 
that help to reduce the number of falls and relieve other negative side effects in the life of 
someone with Parkinson’s might be a key non-medicinal treatment route. This study’s results 
show that there are many unique and different ways for people living with Parkinson’s to 
strengthen their motor control, even though they have a degenerative disease.  One final physical 
therapy strategy that is good for people living with Parkinson’s is basic strength training. While 
muscles weaken naturally as someone gets older, these effects are multiplied in patients with 
Parkinson’s. Doing strength training such as resistance exercises with light dumbbells or a 
resistance band can help the patient maintain positive motor control over their muscles. Pool-
based strength training classes are also great for people living with Parkinson’s because it helps 
to take the excess force off of joints and muscles, while also training and using them in an 
efficient manner.10  
 One of the most important parts of battling with any disease is the mental and 
physiological aspect. If someone is diagnosed with a disease or a condition and they are defeated 
in their minds and they have no hope of ever getting better, then the disease has already won.12 
However, if the person that was diagnosed stays positive about their outcome and truly believes 
they can beat their condition, then their outlook on life and dealing with treatment stays high. 
Many diseases and conditions have support groups where people who are afflicted by said 
disease or condition, can go and talk to and support one another, and Parkinson’s Disease is no 
different. Parkinson’s Disease is a crippling disease that deteriorates their physical and mental 
condition. People with Parkinson’s will eventually lose their ability to live life on their own and 
will no longer be able to control their lives or bodies. However, it has been shown that when 
patients have access to professional or member-led support groups, the acceptance for the disease 
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goes up and patients are better able to cope with its challenges.12 Support groups of any kind are 
also another important part of therapy and learning to live with the disease. Online support 
groups are becoming ever more popular with recent technological advancements.13 Online 
support groups also help people with Parkinson’s because it gives them easy access to help and 
support, without having to leave the comfort of their home.14 In Attard’s journal, she looked at 
how accessing support forums and groups can have a positive impact on people dealing with 
disease, especially Parkinson’s Disease. On these forums and online support groups, people were 
able to offer much valued support and advice, especially during times of crisis or great emotional 
distress. One quote from the forum states that, “the importance of the forums as a source of 
support was apparent as members often expressed their gratitude towards other for informing, 
encouraging, caring, and thinking of them as they battles with the disease”.12 One strength of 
support groups and online forums is that people who have been diagnosed with the disease for a 
longer period of time than others can help guide and share experiences with people who have 
been recently diagnose. Attard stated that sharing personal stories was an integral part of the 
support groups and forums. The forums and groups also allowed people to stay connected and up 
to date on interesting and useful information, as well as keeping up with the latest advances in 
medication/treatment. One of the most important parts of support groups and online forums is 
helping an inflicted individual see that they are not alone in their fight. Attard states that new 
members to the online forum often felt relief when they finally realized that there were other 
people struggling with the same day to day experiences that they were and that they were not 
alone. One final important note about support groups and online forums is that they are an 
incredible tool to help people with that disease to stay encouraged and have positive thinking.15 
Attard states that a number of members would post on the online forum about how they were 
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determined to live a full life and not let their disease or illness dominate their lives.. Being able 
to gain insight from others and to have support on the bad days is just as important as important 
as keeping up with a physical therapy regiment. Mental/emotional therapy can help to strengthen 
the mind and keep the spirts up while dealing with a debilitating disease.16  
 
Current Parkinson’s Disease Treatment Options – Pharmacological   
 Being able to relieve some of the effects of degenerative diseases is key for patients to be 
able to live a mostly normal life. Drugs that can inhibit certain receptors, make missing 
substances out of precursors, and slow down the negative effects of a disease are all important. 
Most disease have some sort of medical treatment available and Parkinson’s Disease is no 
different. One of the most famous drugs used to treat Parkinson’s is Levodopa. In Parkinson’s 
Disease, the cause of the symptoms is due to a decrease in dopamine production.17 More 
specifically, degradation of the substantia nigra occurs and this leads to massive disruption in the 
brain’s nigrostriatal pathway. This leads to one of the common signs of Parkinson’s Disease, a 
decrease in production of dopamine. Levodopa helps to fill the body’s missing dopamine levels 
by administering the precursor so the body can change it into the usable form of dopamine 
easily. Levodopa is very efficient because it can cross the blood-brain-barrier, while regular 
dopamine cannot. Levodopa is commonly taken with carbidopa, which is a dopamine 
decarboxylase inhibitor. The main reason carbidopa is commonly taken along with Levodopa is 
because carbidopa can decrease the amount of levodopa that is converted into dopamine in the 
periphery, so levodopa can cross the blood-brain-barrier and be more effective. Once levodopa 
has crossed the blood-brain-barrier, it is converted into dopamine. This dopamine that is 
produced helps to activate postsynaptic dopaminergic receptors in the brain, which help to 
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compensate for the natural decreased dopamine production.18 It is most commonly used to treat 
Parkinson’s and is usually prescribed once the patient’s symptoms become too severe. 
 Even as powerful as a drug that Levodopa is, its bioavailability is something to be 
concerned about. Its bioavailability when taken orally is only around 30%.19 There has been 
thought that other methods of delivery of this dopamine precursor should be considered. One 
other route that is being explored is delivering Levodopa via an intranasal injection with 
nanoparticles. With this route, it is thought to bypass the blood-brain-barrier and peripheral 
metabolism totally, being delivered to the brain via the olfactory and trigeminal nerve 
pathways.20 Even though this current route of treatment is thought to be more effective and easier 
to administer, it is still in the experimental phase, but it has shown promising results.19,20  
 Other than dopamine precursors, there exists another kind of drug used to treat 
Parkinson’s Disease called dopamine agonists. There are currently 10 dopamine agonists that are 
marketed for the treatment of Parkinson’s. Five of these dopamine agonists are ergot derivatives, 
meaning they are derived from a fungus that produces alkaloids called ergotamines. These 5 
drugs are bromocriptine, cabergoline, dihydroergocryptine, lisuride, and pergolide. The other 5 
dopamine agonists are non-ergot derivatives, and they are apomorphine, piribedil, pramipexole, 
ropinirole, and rotigotine.25 The most popular choice among these dopamine precursors is 
pramipexole. When discussing medicinal treatments for Parkinson’s Disease, it is important to 
understand that different drugs may have different impacts on different people. There is not one 
single treatment option that covers all angles of Parkinson’s, and most times, multiple of these 
drugs are used together to help treat symptoms. It is important to look at each patient as an 
individual and to devise the proper treatment plan for them, and not go off of what worked in the 
treatment of someone else.  
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One commonly seen drug that is used to treatment the symptoms of Parkinson’s Disease 
is Pramipexole. Even though Levodopa is seen as the “golden standard” drug for treating 
Parkinson’s, in recent years, its effectiveness has faded quickly for some patients and it has been 
known to cause extreme motor fluctuations as well.21 Pramipexole is a dopamine agonist, unlike 
levodopa, which is a dopamine precursor. Pramipexole is a non-ergot D2/D3 synthetic 
aminobenzothiazole derivative that is found to be an effective monotherapy is patients that have 
been recently diagnosed with Parkinson’s Disease.22 Pramipexole, when taken, has selective 
affinity and action at dopamine receptors in the brain that belong to the D2 subfamily. When 
pramipexole is bound to these receptors, it is seen to have full activity similar to if sufficient 
levels of dopamine were present. With this specific drug activating dopamine receptors, instead 
of making dopamine like levodopa, it has shown been shown to not cause as severe muscle and 
motor fluctuations in patients.23 One other dopamine agonist that has seen wide usage to treat 
Parkinson’s Disease is ropinirole. Ropinirole was widely accepted as a transdermal patch 
delivery to help treat early Parkinson’s, but it has been withdrawn from the US markets, due to 
the drug crystalizing in the patch.24  
In the table below, there is a comparison for levodopa vs dopamine agonists in the 
treatment for Parkinson’s Disease. While both drugs have the potential to show possible 
neurotoxic or neuroprotective effects in vitro, both drugs have strong evidence of no neurotoxic 
or neuroprotective effects in patients with Parkinson’s disease.26 Levodopa has shown to provide 
better motor efficacy in the early years after diagnosis and treatment has begun, but the side 
effects of levodopa have been shown to be at an increased level as well. Levodopa is shown to 
have more motor fluctuations and have earlier onset dyskinesia than dopamine agonists. While 
the dopamine agonists do not have as severe side effects of levodopa, the motor efficacy is lower 
15 
 
in patients that take this drug over levodopa.27 Overall, both drugs are extremely effective at 
improving the quality of life of someone that has Parkinson’s Disease.25  
Table 5. Levodopa vs Dopamine Agonists.25   
 
 One interesting side effect of Parkinson’s Disease is psychotic symptoms that become 
prevalent due to the continuum of Parkinson’s Disease progression. The National Institute of 
Neurological Disorders and Stroke and National Institute of Mental Health use the term “PD 
psychosis” (PDP) to describe these symptoms.28 When dealing with PD psychosis, criteria for a 
correct diagnosis of psychosis caused by Parkinson’s Disease must be met. These criteria are: (1) 
The presence of at least one of the following symptoms: illusions, false sense of presence, 
hallucinations, or delusions; (2) A diagnosis of Parkinson’s Disease before any of the symptoms 
started to occur; (3) The symptoms are recurrent or continuous for at least 1 month; (4) The 
symptoms aren’t better classified as another mental health disorder such as dementia, 
schizophrenia, delusional disorder, and mood disorders.29 PDP may occur partially due to the 
medications that a patient is taking to treat their Parkinson’s symptoms. These drugs include 
levodopa and dopamine agonists, which were both discussed above. Levodopa and dopamine 
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agonists are crucial drugs in helping to treat the symptoms of Parkinson’s Disease and can not 
stop being administered. There have been different drug trials to try and find a solutions for these 
psychotic symptoms, and one medication has shown strong indications of being able to treat 
those symptoms. Pimavanserin, otherwise known as Nuplazid, is an atypical antipsychotic 
medication, and is also the first medication that has been approved by the FDA to help treat the 
symptoms of hallucinations and delusions associated with Parkinson’s Disease psychosis.30 One 
of the main reasons that this specific drug is effective at treating these symptoms is because it 
does not have affinity and lacks activity at dopaminergic, muscarinic, adrenergic, and 
histaminergic receptors, meaning it does not interact or block the treatment routes of levodopa 
and dopamine antagonists. It has also shown to not have any serious adverse side effects and 
does not worsen the motor symptoms of Parkinson’s Disease.30 
 
Conclusion 
 Parkinson’s Disease is a chronic and progressive neurodegenerative disorder that impairs 
motor function, presents bradykinesia, rigidity, and postural instability. This paper has explored 
different treatment options for patients that are currently available to treat the symptoms of 
Parkinson’s Disease. While there is no cure for Parkinson’s, a combination of pharmacological 
and non-pharmacological treatment methods is the best way to combat the symptoms that 
Parkinson’s Disease shows. There is no one drug or physical therapy method that is the best 
option for treatment. Exploring different treatment routes and finding what is best for the patient 
should always be desired. I hope this paper has shown that there are different methods to treating 
Parkinson’s Disease, and hopefully one day, a cure will be found to rid the world of this disease.  
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Potential Future Work With Topic 
 Parkinson’s Disease is a crippling disease that affects millions of people around the 
world, including some of my close and immediate family. In the future, I am planning on going 
to medical school and I think it would be very interesting to do research, if possible, for future 
drugs to help treat Parkinson’s Disease, or even a cure for it. I plan on continuing my own 
research into different treatment methods and looking into up and coming drugs that could help 
to end this disease and staying educated on this topic.  
 
Acknowledgements  
 I would like to thank my advisor, Dr. Greg Heiberger, on helping guide me through this 
process of research and writing this paper. I would also like to thank my external reviewer, Dr. 
Michael Heisler, for providing excellent feedback and ideas when necessary. I would like to 
thank my in-class reviewers, Emily Steadman and Tayt Boeckholt, for providing great feedback 














1. Wood-Kaczmar, A., et al. (2006). "Understanding the molecular causes of Parkinson's 
disease." Trends in Molecular Medicine 12(11): 521-528. 
2. Cookson, M. R. (2005). "THE BIOCHEMISTRY OF PARKINSON'S DISEASE." 
Annual Review of Biochemistry 74(1): 29-52. 
3. Singleton, A. B., et al. (2013). "The genetics of Parkinson's disease: Progress and 
therapeutic implications." Movement Disorders 28(1): 14-23. 
4. Singleton, A. B. (2003). "-Synuclein Locus Triplication Causes Parkinson's Disease." 
Science 302(5646): 841-841. 
5. Galter, D., et al. (2006). "LRRK2 expression linked to dopamine-innervated areas." 
Annals of Neurology 59(4): 714-719. 
6. Abou-Sleiman, P. M., et al. (2006). "A heterozygous effect for PINK1 mutations in 
Parkinson's disease?" Annals of Neurology 60(4): 414-419.   
7. Montgomery, E. B. (2004). "Rehabilitative approaches to Parkinson's disease." 
Parkinsonism & Related Disorders 10: S43-S47. 
8. Dibble, L., et al. (2009). “The Effects of Exercise on Balance in Persons with Parkinson’s 
Disease: A Systematic Review Across the Disability Spectrum.” Journal of Neurologic 
Physical Therapy 33(1): 14-26.  
9. Lauzé, M., et al. (2016). "The Effects of Physical Activity in Parkinson’s Disease: A 
Review." Journal of Parkinson's Disease 6(4): 685-698. 
10. Medicine, J. H. (2018). "Physical Therapy for Parkinson's Disease." Retrieved 
10/30/2019, 2019. https://www.hopkinsmedicine.org/health/conditions-and-
diseases/physical-therapy-for-parkinsons-disease 
11. Li, F., et al. (2012). "Tai Chi and Postural Stability in Patients with Parkinson's Disease." 
New England Journal of Medicine 366(6): 511-519. 
12. Attard, A. and N. S. Coulson (2012). "A thematic analysis of patient communication in 
Parkinson’s disease online support group discussion forums." Computers in Human 
Behavior 28(2): 500-506. 
13. Barak, A., et al. (2008). “Fostering Empowerment in Online Support Groups.” 
Computers in Human Behavior, 24, 1867-1883.  
14. Braithwaite, D. et al. (1999). “Communication of Social Support in Computer-Mediated 
Groups for People with Disabilities.” Health Communication, 11, 123-151.  
15. Charlton, G. S. et al. (2002). “Coping with Self-Help Group Membership in Parkinson’s 
Disease: An Exploratory Qualitative Study.” Health and Social Care in the Community, 
10, 472-478.  
16. Finn, J. (1999). “An Exploration of Helping Processes in an Online Self-Help Group 
focusing on Issues of Disability.” Health and Social Work, 24, 220-231.  
17. Gandhi, KR. (Updated Mar 21, 2019). “Levodopa (L-Dopa). StatPearls Publishing; 2019 
Jan. Accessed December 14th, 2019. https://www.ncbi.nlm.nih.gov/books/NBK482140/ 




19. Sharma S, Lohan S, Murthy RSR. Formulation and characterization of intranasal 
mucoadhesive nanoparticulates and thermo-reversible gel of levodopa for brain delivery. 
Drug Dev Ind Pharm. 2013;9045:1-10.  
20. Kulkarni AD, Vanjari YH, Sancheti KH, Belgamwar VS, Surana SJ, Pardeshi CV. 
Nanotechnology-mediated nose to brain drug delivery for Parkinson’s disease: a mini 
review. J Drug Target. 2015;(August):1-14.  
21. Salawu, F. (2012). "Patient considerations in early management of Parkinson&rsquo;s 
disease: focus on extended-release pramipexole." Patient Preference and Adherence: 49. 
22. Jenner P, Konen-Bergmann M, Scheprs C, Haertter S. Pharmacokinetics of a once-daily 
extended release formulation of pramipexole in healthy male volunteers: three studies. 
Clin Ther. 2009;31:2698-2711.  
23. Olanow W, Schapiro AH, Rascol O. Continuous dopamine-receptor stimulation in early 
Parkinson’s disease. Neurology. 2007;68:1108-1115.  
24. Olanow CW, Stern MB, Sethi K. The scientific and clinical basis for the treatment of 
Parkinson’s disease 2009. Neurology. 2009;72(21 Suppl 4): S1-136.  
25. Zhang, J. and L. Chew-Seng Tan (2016). "Revisiting the Medical Management of 
Parkinson's Disease: Levodopa versus Dopamine Agonist." Current Neuropharmacology 
14(4): 356-363. 
26. Murer,  M.G.;  Dziewczapolski,  G.;  Menalled,  L.B.;  Garcia,  M.C.; Agid,  Y.;  
Gershanik,  O.;  Raisman-Vozari,  R.  Chronic levodopa  is not  toxic  for  remaining  
dopamine  neurons,  but  instead  promotes their  recovery,  in  rats  with  moderate  
nigrostriatal  lesions. Ann. Neurol., 1998, 43(5),   561-575. 
27. Weiner,  W.J.;  Reich,  S.G.  Agonist  or  levodopa  for  Parkinson disease?:  ultimately,  
it  doesn't  matter;  neither  is  good  enough. Neurology, 2008, 71(7),   470-471. 
28. Ravina B, Marder K, Fernandez HH, Friedman JH, McDonald W, Murphy D, Aarsland 
D, Babcock D, Cummings J, Endicott J, Factor S, Galpern W, Lees A, Marsh L, Stacy M, 
Gwinn-Hardy K, Voon V, Goetz C. Diagnostic criteria for psychosis in Parkinson's 
disease: report of an NINDS, NIMH work group. Mov Disord. 2007;22:1061–1068. 
29. Tampi, R. R., et al. (2019). "Evidence for using pimavanserin for the treatment of 
Parkinson's disease psychosis." World Journal of Psychiatry 9(3): 47-54. 
30. Bozymski KM, Lowe DK, Pasternak KM, Gatesman TL, Crouse EL. Pimavanserin: A 
Novel Antipsychotic for Parkinson's Disease Psychosis. Ann 
Pharmacother. 2017;51:479–487. 
